Zhixiang Jintai: GR2303 injection received approval for clinical trials of the drug.

Zhixiang Jintai Announcement, recently, the company received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for the investigational product GR2303 injection has been approved. GR2303 injection is a recombinant fully human anti-tumor necrosis factor ligand 1A monoclonal antibody developed independently by the company. The product can target binding TL1A, block the binding of TL1A to death receptor 3, thereby inhibiting the downstream pathway signal transduction caused by TL1A, reducing the release of pro-inflammatory factors, and achieving the effect of treating inflammatory bowel disease.